Allogene Therapeutics (ALLO) stock
ALLO's Quality Score rose 1 point on Mon, Oct 5, to -4. Closed near the day's high.
Follow ALLO's trial news. Pro members can get an alert when Allogene Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
What's next for ALLO, and how long its cash lasts
From Allogene Therapeutics’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.
Next step the company has named
Cash runway
The company says its cash lasts into 2029 (8-K, Aug 12).
Dilution on the horizon
- Shelf registration (S-3, filed Aug 12, 2026)
- At-the-market share sales program (S-3, filed Aug 12, 2026)
Insiders
SVP, General Counsel Earl Martin Douglas sold 29,697 shares on Aug 21. 12 more insider trades this year.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.
- In 24 daysINOInovio Pharmaceuticals
INOINO-3107
- In 35 daysNRXPNRX Pharmaceuticals
NRXPDrug not named
- In 47 daysCAPRCapricor Therapeutics
CAPRDrug not named
Why it's down
Down 28% in 3 months, 20% under its 50-day average.
Down more than its industry: the 299 other stocks in it fell a median 14% over the same 3 months.
−2Long-term trend below a falling 200-day average, down over two years
3 more things pulling ALLO's score down, for Pro members
What's next
Expected to report Thu Nov 5, after the close
After its last 4 reports it closed -0.7% on average, higher 1 of 4 times.
What would turn ALLO's score around: 8 things, for Pro members
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
ALLO has 2 of 14 checks firing
One per group is shown here.
Also on the chart
- RSI 1425.3
- MACD (12, 26, 9)Below signal
- 50-day average$1.87
- 200-day average$1.99
- ADX 1435.3
- Support$1.45
- Resistance$1.52
- Bollinger Bands (20, 2)Inside
- Volume0.8x
How ALLO ranks in Biotech
ALLO is #233 of 300 by Quality Score. The top three are shown with their scores, and more by name.
ONC8/1420
RGEN8/1420
CORT8/1418
ALDXOpen for its score
ALECOpen for its score
ALNYOpen for its score
ALTOpen for its score
ALLO2/14-4
When does ALLO report earnings, and what happens after?
Expected to report Thu Nov 5, after the close (in 30 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 12, 2026After close | After close | +2.9% | -4.3% | +7.7% |
| May 13, 2026After close | After close | -1.3% | -8.2% | -18.4% |
| Mar 12, 2026After close | After close | +3.6% | -2.8% | -10.1% |
| Nov 6, 2025After close | After close | 0.0% | +12.4% | +14.3% |
Who is trading ALLO
ALLO insider trades
One insider sold $63K across 1 filing in the last 6 months. No open-market buys on record. The newest:
About Allogene Therapeutics
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
Pro members see every line of every stock's score.
- Real-time prices, no delay
- Every line of ALLO's score, with the points and the reason
- All 14 checks on ALLO and on all 3,243 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on ALLO
Straight Answers
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.
Do I need an account?
Not to start. Tap any green button and you're in, free, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.